|1.||Kingery, Wade S: 7 articles (10/2012 - 07/2003)|
|2.||Guo, Tian-Zhi: 5 articles (10/2012 - 03/2004)|
|3.||Shi, Xiaoyou: 3 articles (10/2012 - 10/2009)|
|4.||Clark, J David: 3 articles (12/2009 - 07/2003)|
|5.||Goldstein, D J: 3 articles (03/2001 - 04/2000)|
|6.||Yeomans, David C: 2 articles (10/2012 - 10/2009)|
|7.||Liang, Deyong: 2 articles (10/2012 - 12/2009)|
|8.||Sahbaie, Peyman: 2 articles (10/2012 - 10/2009)|
|9.||Qiao, Yanli: 2 articles (10/2012 - 10/2009)|
|10.||Wei, Tzuping: 2 articles (01/2012 - 12/2009)|
|1.||Migraine Disorders (Migraine)
03/01/2001 - "In this study lanepitant was not effective in preventing migraine, but was well tolerated. "
03/01/2001 - "This study evaluated the effect of lanepitant taken daily for migraine prevention. "
11/01/1997 - "Lanepitant was ineffective orally in treating acute migraine in this trial. "
03/01/2001 - "Lanepitant, an NK-1 antagonist, in migraine prevention."
11/01/1997 - "Additionally, there was no change in severity of migraine-associated symptoms associated with lanepitant therapy. "
01/01/1997 - "LY303870 administration potently inhibited neurogenic dural inflammation as measured by plasma protein extravasation caused by electrical stimulation of the trigeminal ganglion in guinea pigs. "
01/01/1997 - "LY303870, at oral doses of 1, 10 and 100 microg/kg, produced a long, dose-dependent inhibition of dural inflammation, demonstrating a suitable duration of action for a potential use in acute migraine and migraine prophylaxis."
01/01/1997 - "The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs."
11/01/1997 - "Lanepitant is a high-affinity, selective neurokinin-1 receptor (NK-1) and is effective in the dural inflammation model of acute migraine. "
03/01/2001 - "Lanepitant, a potent non-peptide neurokinin-1 receptor antagonist, inhibits neurogenic dural inflammation, and may have a role in migraine therapy. "
10/01/2014 - "Topical Lanepitant was nontoxic to the ocular surface and effective in reducing hemangiogenesis and lymphangiogenesis, corneal SP levels, and leukocyte infiltration, as soon as 4 days later in the alkali burn model. "
10/01/2014 - "Additionally, in the alkali burn model, subconjunctival Lanepitant significantly reduced blood CNV, corneal perforation rate, opacity, and leukocyte infiltration, and improved tear secretion. "
04/01/2000 - "Study of the analgesic effect of lanepitant in patients with osteoarthritis pain."
01/01/2001 - "Although well tolerated, lanepitant was ineffective in relieving pain of diabetic neuropathy."
04/01/2000 - "We investigated the effect of lanepitant on pain caused by osteoarthritis to evaluate the role of neurokinin-1 blockade. "
11/01/1997 - "Lanepitant 30, 80, and 240 mg given orally was evaluated in a double-blind, placebo-controlled crossover study to determine its effect in reducing migraine pain and severity of associated symptoms. "
04/01/2000 - "During the second and third weeks of therapy, patients receiving naproxen continued to have statistically significantly (P < .05) less pain than those receiving placebo or lanepitant despite using significantly less adjunctive analgesic medication. "
|1.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|6.||Nerve Growth Factor (NGF)
|7.||Interleukin-18 (Interleukin 18)
|10.||Interleukin-6 (Interleukin 6)